Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
This study has previously been registered by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of this study.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Metastatic breast cancer (meaning the cancer has spread beyond its original location)
At least one measurable lesion by CT or MRI
Progression of disease following previous therapy for breast cancer
Have received previous treatment with anthracyclines (e.g. doxorubicin\[Adriamycin or Doxil\] or epirubicin \[Ellence\]), taxanes (paclitaxel \[Taxol or Abraxane\] or docetaxel \[taxotere\]) for your breast cancer
Not be pregnant
Additional criteria to be determined at screening visit.
You may not be if
More than 3 previous chemotherapy regimens
More than one treatment with non cytotoxic agents for breast cancer therapy (e.g. herceptin \[trastuzumab\] or Avastin \[bevacizumab)
Prior treatment with epothilones (e.g. Ixabepilone)
Symptomatic brain metastases
Additional criteria to be determined at screening visit
